VALN Overview
Upcoming Projects (VALN)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (VALN)
-
A Third View: Looking into the phase 2 VLA15-221 clinical trial data on Valneva's Lyme disease vaccine candidate.
Ticker: VALN
Executed On: Nov 13, 2024 at 12:15 PM EST -
A Second View: Looking into the phase 2 VLA15-221 clinical trial data on Valneva's Lyme disease vaccine candidate.
Ticker: VALN
Executed On: Oct 10, 2024 at 12:00 PM EDT -
Looking into the phase 2 VLA15-221 clinical trial data on Valneva's Lyme disease vaccine candidate.
Ticker: VALN
Executed On: Oct 10, 2024 at 10:00 AM EDT -
Examining the standard of care and the potential of VLA15 after the positive Phase 2 booster results for Lyme Disease vaccine candidate VLA15 by Pfizer and Valneva SE
Tickers: PFE, VALN
Executed On: Oct 12, 2023 at 02:35 PM EDT -
A Third Look: Discussing the potential of Valneva's single-shot chikungunya vaccine candidate, VLA1553.
Ticker: VALN
Executed On: Sep 21, 2023 at 02:00 PM EDT -
A Second Look: Discussing the potential of Valneva's single-shot chikungunya vaccine candidate, VLA1553.
Ticker: VALN
Executed On: Sep 20, 2023 at 09:00 AM EDT -
Discussing the potential of Valneva's single-shot chikungunya vaccine candidate, VLA1553.
Ticker: VALN
Executed On: Sep 19, 2023 at 10:00 AM EDT -
Discussing the current standard of care and the potential of VLA15, a multivalent recombinant protein vaccine candidate that targets six serotypes of Borrelia currently in development by Valneva and Pfizer.
Tickers: VALN, PFE
Executed On: Oct 31, 2022 at 12:00 PM EDT
Upcoming & Overdue Catalysts (VALN)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (VALN)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
